 |
20 Diseases |  |
29 Trials |
|
29 Trials |  |
1253 News |  |
| «12...891011121314151617181920» |
- |||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment open, Trial primary completion date: GS-US-342-4062: Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease (clinicaltrials.gov) - Apr 6, 2017
P2, N=100, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2018 --> Jul 2018
- || sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant (clinicaltrials.gov) - Mar 29, 2017
P2, N=79, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2018 --> Jul 2018 Trial primary completion date: Mar 2017 --> Aug 2017
- || ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: GS-US-342-2097: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis (clinicaltrials.gov) - Mar 24, 2017
P2, N=200, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Mar 2017 --> Aug 2017 Trial primary completion date: Mar 2017 --> Oct 2017
- | sofosbuvir/velpatasvir / Generic mfg.
New P4 trial: Transplanting Hepatitis C Positive Organs (clinicaltrials.gov) - Mar 22, 2017
P4, N=32, Not yet recruiting, Sponsor: Brigham and Women's Hospital
- |||||||||| sofosbuvir/velpatasvir / Generic mfg.
New P3 trial: GS-US-342-1521: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Mar 8, 2017
P3, N=125, Not yet recruiting, Sponsor: Gilead Sciences
- ||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant (clinicaltrials.gov) - Feb 27, 2017
P2, N=79, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Mar 2017 --> Oct 2017 Recruiting --> Active, not recruiting
- | ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis (clinicaltrials.gov) - Feb 27, 2017
P2, N=50, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | sofosbuvir/velpatasvir / Generic mfg.
New P4 trial: Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection (clinicaltrials.gov) - Feb 19, 2017
P4, N=75, Not yet recruiting, Sponsor: University of Pittsburgh
- | sofosbuvir/velpatasvir / Generic mfg., daclatasvir/sofosbuvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: REDEMPTION: Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=10000, Enrolling by invitation, Sponsor: FixHepC
Not yet recruiting --> Recruiting Active, not recruiting --> Enrolling by invitation
- sofosbuvir/velpatasvir / Generic mfg., daclatasvir/sofosbuvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Trial primary completion date: REDEMPTION: Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods (clinicaltrials.gov) - Feb 15, 2017
P=N/A, N=10000, Active, not recruiting, Sponsor: FixHepC
Active, not recruiting --> Enrolling by invitation Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jan 2017
- ||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: GS-US-342-1522: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Feb 8, 2017
P3, N=119, Active, not recruiting, Sponsor: Gilead Sciences
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jan 2017 Recruiting --> Active, not recruiting
- ||||| sofosbuvir/velpatasvir / Generic mfg.
New P2 trial: GS-US-342-4062: Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease (clinicaltrials.gov) - Jan 30, 2017
P2, N=100, Not yet recruiting, Sponsor: Gilead Sciences
- ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial (clinicaltrials.gov) - Jan 26, 2017
P4, N=10, Not yet recruiting, Sponsor: Ala'a Sharara
- |||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: Efficacy and Safety of Sofosbuvir/Velpatasvir (clinicaltrials.gov) - Jan 24, 2017
P3, N=100, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| sofosbuvir/velpatasvir / Generic mfg.
New P2 trial: Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection (clinicaltrials.gov) - Jan 18, 2017
P2, N=200, Recruiting, Sponsor: Gilead Sciences
- | sofosbuvir/velpatasvir / Generic mfg.
New P4 trial: CHIP: Curing HCV in Incarcerated Patients (clinicaltrials.gov) - Jan 12, 2017
P4, N=100, Not yet recruiting, Sponsor: San Francisco Department of Public Health
- |||||||||| sofosbuvir/velpatasvir / Generic mfg.
New P3 trial: Efficacy and Safety of Sofosbuvir/Velpatasvir (clinicaltrials.gov) - Dec 19, 2016
P3, N=100, Not yet recruiting, Sponsor: Gilead Sciences
- | ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
New P2 trial: Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis (clinicaltrials.gov) - Dec 15, 2016
P2, N=50, Not yet recruiting, Sponsor: Gilead Sciences
- sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation (clinicaltrials.gov) - Nov 18, 2016
P2, N=10, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Sep 2017
- |||| ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Trial completion, Enrollment change: Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study (clinicaltrials.gov) - Oct 11, 2016
P2, N=69, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Jun 2017 --> Sep 2017 Active, not recruiting --> Completed | N=150 --> 69
- ||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen (clinicaltrials.gov) - Oct 5, 2016
P3, N=117, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | N=150 --> 69 Recruiting --> Active, not recruiting
- |||| sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: GS-US-342-1518: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV (clinicaltrials.gov) - Sep 14, 2016
P3, N=360, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Jan 2018
- |||| sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: GS-US-342-1522: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Sep 12, 2016
P3, N=120, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2017 --> Jan 2018 Trial primary completion date: Dec 2016 --> Jul 2017
- sofosbuvir/velpatasvir / Generic mfg.
Enrollment change, Trial primary completion date: SToP-C: Surveillance and Treatment of Prisoners With Hepatitis C (clinicaltrials.gov) - Aug 31, 2016
P4, N=1200, Recruiting, Sponsor: Kirby Institute
Trial primary completion date: Dec 2016 --> Jul 2017 N=650 --> 1200 | Trial primary completion date: Dec 2017 --> Dec 2018
- |||| ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: GS-US-342-2097: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis (clinicaltrials.gov) - Aug 8, 2016
P2, N=200, Recruiting, Sponsor: Gilead Sciences
N=650 --> 1200 | Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- |||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen (clinicaltrials.gov) - Aug 2, 2016
P3, N=110, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant (clinicaltrials.gov) - Jul 28, 2016
P2, N=80, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: BArT: Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection (clinicaltrials.gov) - Jul 19, 2016
P2, N=50, Recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
- | sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2/3 trial: Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia (clinicaltrials.gov) - Jul 7, 2016
P2/3, N=10, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- ||||||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection (clinicaltrials.gov) - Jul 7, 2016
P3, N=107, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| sofosbuvir/velpatasvir / Generic mfg.
New P3 trial: Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen (clinicaltrials.gov) - Jul 5, 2016
P3, N=110, Not yet recruiting, Sponsor: Gilead Sciences
- ||||||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: GS-US-342-1446: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection (clinicaltrials.gov) - Jun 22, 2016
P3, N=111, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- sofosbuvir/velpatasvir / Generic mfg.
Enrollment open, Trial primary completion date: Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation (clinicaltrials.gov) - Jun 20, 2016
P2, N=10, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Jun 2017
- ||||| ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
New P2 trial: GS-US-342-2097: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis (clinicaltrials.gov) - May 24, 2016
P2, N=200, Not yet recruiting, Sponsor: Gilead Sciences
- ||||| sofosbuvir/velpatasvir / Generic mfg.
New P2 trial: Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant (clinicaltrials.gov) - May 24, 2016
P2, N=80, Not yet recruiting, Sponsor: Gilead Sciences
- |||| voxilaprevir (GS-9857) / Gilead
Trial completion: LEPTON: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (clinicaltrials.gov) - May 13, 2016
P2, N=269, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Jun 2017 Active, not recruiting --> Completed
- |||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: GS-US-342-1522: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - May 4, 2016
P3, N=120, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment open, Trial primary completion date: GS-US-342-1518: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV (clinicaltrials.gov) - Apr 27, 2016
P3, N=360, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Sep 2017
- sofosbuvir/velpatasvir / Generic mfg.
New P2 trial: Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation (clinicaltrials.gov) - Apr 6, 2016
P2, N=10, Not yet recruiting, Sponsor: Gilead Sciences
- |||||||||| sofosbuvir/velpatasvir / Generic mfg.
New P3 trial: GS-US-342-1522: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Mar 30, 2016
P3, N=120, Not yet recruiting, Sponsor: Gilead Sciences
- |||||||||| sofosbuvir/velpatasvir / Generic mfg.
New P3 trial: GS-US-342-1518: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV (clinicaltrials.gov) - Feb 2, 2016
P3, N=360, Not yet recruiting, Sponsor: Gilead Sciences
- |||| sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: GS-US-342-1446: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection (clinicaltrials.gov) - Jan 19, 2016
P3, N=111, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Sep 2017 Trial primary completion date: Dec 2015 --> Mar 2016
- sofosbuvir/velpatasvir / Generic mfg., daclatasvir/sofosbuvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New trial: REDEMPTION: Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods (clinicaltrials.gov) - Jan 19, 2016
P=N/A, N=10000, Enrolling by invitation, Sponsor: FixHepC
- ||| Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Sovaldi (sofosbuvir) / Gilead
Enrollment open: A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials (clinicaltrials.gov) - Dec 11, 2015
P=N/A, N=500, Enrolling by invitation, Sponsor: Gilead Sciences
Trial primary completion date: Dec 2015 --> Mar 2016 Not yet recruiting --> Enrolling by invitation
- ||||||| ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Trial completion: ASTRAL-3: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection (clinicaltrials.gov) - Dec 11, 2015
P3, N=558, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- ||||||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: ASTRAL-4: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis (clinicaltrials.gov) - Dec 11, 2015
P3, N=268, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study (clinicaltrials.gov) - Dec 4, 2015
P2, N=150, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection (clinicaltrials.gov) - Nov 17, 2015
P3, N=100, Active, not recruiting, Sponsor: Gilead Sciences
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: GS-US-342-1446: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection (clinicaltrials.gov) - Nov 5, 2015
P3, N=111, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- ||||||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: ASTRAL-1: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection (clinicaltrials.gov) - Oct 9, 2015
P3, N=741, Completed, Sponsor: Gilead Sciences
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed